series-b
Stage
3
Investors
About
Replimune is a clinical-stage biotech company developing oncolytic immunotherapies designed to induce a systemic and durable immune response against a variety of solid tumors.
Explore Replimune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.